Micron Biomedical announced today that it received a $4.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). NIAID (part of the NIH) awarded the contract to Micron to develop a dissolvable microarray medical countermeasure against radiation injury. The contract aims to enable rapid deployment of treatment for Acute Radiation Syndrome (ARS). […]
Funding Roundup
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector
MannKind (Nasdaq:MNKD) announced today that it secured $50 million in a private placement and earned a new regulatory nod. In addition to the funding, the company — which also develops inhaled insulin technology — won FDA approval for the Furoscix ReadyFlow auto-injector. MannKind said it entered into a securities purchase agreement in connection with a […]
Glucotrack, Lōkahi secure financing for completed merger
Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with Lōkahi Therapeutics. The bridge financing, designed to support their strategic growth objectives, allows for the completion of the combination to proceed. Glucotrack did not disclose the terms of the financing. Earlier this week, the company’s announced their […]
Anodyne picks up $12.6M to advance once-weekly GLP-1 patch
Anodyne Nanotech announced today that it closed a $12.6 million Series A financing to support its transdermal drug delivery technology. Velocity Partners VC led the round with co-leaders Evercurious VC, alongside major participation from Relativity Healthcare Partners. Boston-based Anodyne plans to use proceeds to support the advancement of ANN-101, its once-weekly GLP-1 patch for obesity. […]
CeQur closes $100M Series E to support mealtime insulin patch
CeQur announced today that it closed a $100 million Series E financing round to support its mealtime insulin delivery technology. Horw, Switzerland-based CeQur develops the Simplicity mealtime insulin patch pump system. The wearable, disposable bolus insulin delivery system was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared […]
Advanced NanoTherapies raises $31M for drug-coated balloon tech
Advanced NanoTherapies announced that it closed an oversubscribed Series B financing worth more than $31 million. An undisclosed strategic investor, along with S3 Ventures, co-led the round. The T45 Fund and new and existing investors also participated. Funding adds to $4 million raised in 2023. The funds support the company’s therapies for coronary and peripheral […]
Senseonics amends loan facility, increases borrowing capacity to $140M
Senseonics (NYSE:SENS) announced today that it amended a loan and security agreement to increase its maximum borrowing capacity. The long-term implantable continuous glucose monitor (CGM) maker entered into the agreement with Hercules Capital. It increases its maximum borrowing capacity from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under […]
Senseonics announces $80M public offering
Senseonics (NYSE:SENS) today announced that it commenced an underwritten public offering to sell $80 million in common stock. The offering includes common stock and, for certain investors, pre-funded warrants to purchase common stock. Germantown, Maryland-based Senseonics expects to grant underwriters a 30-day option to purchase. up to an additional 15% of the total number of […]
Vaxess rebrands to Terrestrial Bio, raises $50M for GLP-1 patch
Vaxess Technologies today announced a rebranding to Terrestrial Bio, Inc., along with $50 million in Series C financing. Boston-based Terrestrial Bio rebranded to reflect its strategic focus on transforming the delivery and accessibility of its therapies. That starts with GLP-1 therapeutics, delivered using the company’s microarray patch (MAP). The technology features a soluble microarray with […]
MiniMed completes $538M IPO, retains $309M in proceeds as Medtronic separation takes shape
MiniMed (Nasdaq:MMED) announced today that it completed its previously announced initial public offering (IPO). Shares of MMED began trading on Friday, March 6, following the pricing of the IPO that day. They closed today, March 9, down 2.7% at $18 apiece. The Medtronic Diabetes unit priced its IPO at $20 per share, offering 28 million […]
